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ABSTRACT
Despite well-established treatment regimens, tuberculosis (TB) remains a public health burden; it disproportionately affects poor and marginalized
populations who may not have access to social support, including migrants, homeless people and those dependent on drugs or alcohol. There is a
clearly demonstrated need for housing and other appropriate social support, as part of a package of integrated clinical and social care. However,
TB prevention and control efforts in the UK often do not address the specific vulnerabilities of these groups and it can be a challenge to support
the continued TB treatment of these underserved populations. This challenge is exacerbated by complex issues concerning funding, immigration
and the law. In this paper, we have reviewed current UK guidance and legislation, discussed several case studies and highlighted examples of
existing models of community support for TB patients. Finally, we lay out our recommendations for ensuring a co-ordinated, whole system
approach to successful TB treatment.
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Introduction
Despite well-established treatment regimens, tuberculosis
(TB) remains a public health burden; it disproportionately
affects poor and marginalized populations who may not have
access to social support, including migrants, homeless people
and those dependent on drugs or alcohol. TB prevention and
control efforts in the UK often do not address the specific
vulnerabilities of these groups and it can be a challenge to
support the continued TB treatment of these underserved
populations. This challenge is exacerbated by complex issues
concerning funding, immigration and the law.
Although TB medication is free in the UK, evidence shows
that a lack of access to funds to support vulnerable patients, who
in some cases will have no recourse to public funds (NRPF), se-
verely compromises treatment access, completion and cure.1,2
Prolonged or interrupted treatment has a negative impact on the
health of the individual as well as on the wider public health, and
increases costs to health and social care services.
There is a clearly demonstrated need for housing and other
appropriate social support, as part of a package of integrated
clinical and social care. This will vary from case to case and
may include low-cost interventions such as those met by TB
Alert, the UK’s national TB charity, whose Patient Support
Fund has provided funding for needs such as food to support
the effectiveness of medication, travel costs to clinic and
mobile phones/top ups for patients to maintain contact with
nurses.
This paper sets out current UK guidance and legislation,
together with case studies and examples of existing models of
community support for TB patients. It makes UK-based
recommendations for ensuring a co-ordinated, whole system
approach to successful TB treatment.
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Current guidance
The National Institute for Health and Care Excellence
(NICE) provides UK national guidance and advice to
improve health and social care. In 2013, NICE released a
briefing on TB treatment in vulnerable groups3 to local au-
thorities. It was supported by Public Health England and
stated that ‘services provided or commissioned by local public
health teams and other local authority departments tackle the
factors that make people vulnerable to TB and which can
stop them from completing treatment. Local authority
support, welfare and housing services are a vital part of TB
prevention and control for vulnerable groups of people’.
In its guidance on identifying and treating TB in under-
served groups,4 NICE recommends that ‘commissioners of
TB prevention and control programmes should fund accom-
modation for homeless people diagnosed with active TB who
are otherwise ineligible for state-funded accommodation.
Health or public health resources should be used’ and also
that ‘local multidisciplinary teams have access to funds that
can be used flexibly to improve adherence to treatment
among hard-to-reach groups. For example, funds could be
used to provide transport to clinics, to provide incentives for
treatment’.
The Royal College of Nursing (RCN) guidance on
Tuberculosis Case Management5 also highlights the negative
impact that lack of housing, transport, poor nutrition and im-
migration status can have on treatment outcomes. ‘For TB
patients on treatment, the importance of housing cannot be
understated’. The RCN recommends that ‘for the purposes
of TB control, a broad and inclusive definition of homeless-
ness is needed which incorporates overcrowded and sub-
standard accommodation to include people:
† who share an enclosed air space with individuals at high
risk of undetected active pulmonary tuberculosis (that is,
those with a history of rough sleeping, hostel residence or
substance misuse)
† without the means to securely store prescribed medication
† without private space in which to self-administer TB
treatment
† without secure accommodation in which to rest and recu-
perate in safety and dignity for the full duration of planned
treatment’.
The World Health Organization (WHO) statement on TB
control in vulnerable populations6 discusses a number of dif-
ferent groups, including refugees, asylum seekers, the home-
less and those with substance addiction problems; many of
these groups will have NRPF for a variety of reasons. The
WHO cites evidence which demonstrates that providing
housing and other social needs may reduce hospitalization
and improve treatment completion.
The King’s Fund has also recently published a paper high-
lighting their top 10 priorities for clinical commissioners.7
Number 6 is care co-ordination through integrated health and
social care teams. Although the paper highlights the benefits
for patients with long-term illness, it is equally applicable to
TB patients.
The recently published Collaborative Tuberculosis Strategy
for England (2015–20)8 will establish regional TB Control
Boards. One of the responsibilities of these boards will be to
track the outcomes of the strategy to demonstrate progress
and identify areas requiring greater focus. One of the four
ways success will be measured is through the existence of
‘systematic, joined-up care between health services, health and
social care, public health and housing that specifically reaches
underserved or vulnerable groups’.
Legislation
The National Assistance Act 1948 was established to ensure ap-
propriate care was provided for people who did not pay
National Insurance. Section 21 of the Act gives local author-
ities a duty of care towards any person who has a connection
with the locality so long as the need for care is not due to des-
titution alone. In 2002, an amendment removed this duty of
care for persons who were in the UK illegally. In practice, this
excludes many vulnerable TB patients who have NRPF.
For people who do have a right to remain in the UK, to
gain access to certain means-tested benefits including income
support, housing benefit and universal credit requires demon-
strating habitual residence. Habitual residence has no statutory
definition and is determined on a case-by-case basis. In
general, a person must be resident in the UK and there must
be a degree of permanency about this residence.
For patients who are homeless or have insecure housing
but who would be eligible for assistance, it can be extremely
difficult to demonstrate residence within a local authority,
despite having lived in an area for many years. In some cases,
articles of the European Convention on Human Rights can be used
to support an application for housing and subsistence
support, but this can be a very lengthy process and demon-
strating eligibility can, again, be difficult.
With recent changes, and tighter immigration and benefits
eligibility rules in force from 1 April 2014, this process has
become even more challenging and politically sensitive. It can
be extremely difficult to support TB treatment in the commu-
nity for non-EU residents with NRPF. Recent examples have
shown that this can also be problematic for EU Accession
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Citizens who have a right to remain in the UK but are not eli-
gible for any benefits.
The case study below highlights many of these complexities
which, at the time of writing, remain unresolved; some details
have been changed to protect the anonymity of the patient.
A 40-year-old Lithuanian female with smear-positive pul-
monary multidrug-resistant tuberculosis (MDR-TB) had been
living and working in the UK for 5 years. She lost her job
prior to being diagnosed with TB and her housing situation
became insecure. She ended up either sofa surfing or sleeping
on the street. Treatment for MDR-TB is complex and this
particular patient required the addition of a trial drug which
was made available on a compassionate release basis. After
5 months of treatment in a negative pressure room at a neigh-
bouring hospital, she was discharged back to her local hos-
pital. Despite efforts by the health services to have the local
authority house, this patient for the remainder of her treat-
ment, she continued to remain in hospital for a further
10 weeks at significant cost to the NHS.
Although, as an EEA national, this woman had a right to
remain in the UK, she could not demonstrate habitual resi-
dency. However, there is no need to demonstrate habitual resi-
dency for individuals who are no longer in work due to
incapacity or those who are already receiving Jobseeker’s
Allowance. This particular patient had lost her job just prior to
her diagnosis with MDR-TB, possibly due to her illness. She
did not immediately claim Jobseeker’s Allowance after being
made unemployed, which later created difficulties in proving
her housing eligibility. It is also worth noting that her drug
treatment regimen is unavailable in her home country and, as
such, deportation might put her life at risk. This may fall
within the remit of Article 2 of the European Convention on
Human Rights, which declares that the state has, in some cir-
cumstances, a positive duty to prevent a foreseeable loss of life.
Despite all this, she was deemed ineligible for support follow-
ing an assessment by the local authority social services team.
This patient’s TB was complex and should she have
defaulted from treatment, she was likely to become infectious
again and pose a health protection risk. This case highlights the
legal complexities and the importance of supporting vulnerable
patients throughout their TB treatment, taking into account the
overall cost to the public purse and the public health risk.
Benefits of providing support
to vulnerable patients
Without access to public funds, treatment access, completion
and cure are compromised. This can lead to increased illness
of the individual and even death, higher rates of transmission
to the wider public and higher costs.
The following excerpt is from unpublished work con-
ducted by Sue Collinson, TB outreach worker at Homerton
Hospital, London,9 and based on London costs:
Patients with no recourse to public funds or services such
as temporary accommodation could remain on hospital
wards as ‘bed blockers’ at considerable expense to the
NHS. Alternatively, they could self-discharge and discon-
tinue treatment. The two case studies below are real, and
based on the cost of a hospital bed per night (£500).
Case study 1
This was a 46-year-old Jamaican man, with smear positive
pulmonary tuberculosis. Whilst an in-patient, it became
clear that he had NRPF. He spent over five months ‘bed
blocking’ because there was nowhere to discharge him to.
At £500 a night, this cost the NHS at least £77,500.
Case study 2
This was a 47-year-old Polish man who spoke no English. He
had no recourse to public funds. He stayed in a hospital side
room for about three weeks because there was nowhere safe
to discharge him to, and became an expensive bed blocker,
but once he felt fit and well he became bored and self-
discharged. The team continued directly observed treatment
(DOT) at his squat, but within a few weeks he disappeared,
because his squat was closed down and he was lost to follow
up. He died about two months later, but in the meantime had
infected four other people with TB. Death is expensive; the
average cost of a death in London is £9556—almost the
price of two standard six-month courses of TB treatment.
The standard six-month course of TB treatment costs in
excess of £5000. Six months of local authority temporary
accommodation costs £350 per week. The cost of housing
a patient with TB in temporary accommodation and
keeping them adherent on the standard six-month course
is approximately £14,100.
Current models
Local authority support of patients with NRPF is, at best,
ad hoc and relies on local discretion. A number of local author-
ities, such as Islington Council, have established specialist
teams to manage complex cases. The NRPF network, a
network of local authorities and partner organizations focus-
ing on the statutory response to migrants with care needs
who have NRPF, and which provides training and practice
guidance, notes in its 2011 report10 that:
Social services departments in 51 local authorities across the
UK supported approximately 6,500 people with NRPF in
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the financial year 2009/10 at a cost of £46.5 m. Support in
the form of accommodation, subsistence and in some cir-
cumstances additional social care, is provided owing to statu-
tory duties under community care and children’s legislation
and remains unfunded. Local authorities must therefore meet
these costs from existing budgets. This shortfall will become
increasingly acute following cuts to local authority budgets as
part of the Comprehensive Spending Review, particularly for
authorities supporting large numbers of NRPF clients.
Owing to current legislation, individuals with NRPF who
require support need to be discussed on a case-by-case basis
with the local authority concerned. The delay in accessing
funds is variable as is the success of each application.
The TB Team at Homerton Hospital, London, has nego-
tiated a service level agreement with Hackney Council’s
Homeless Person Unit to provide rapid access to accommo-
dation for TB patients with NRPF. This project has been
running for over 4 years and has demonstrated clear cost-
effectiveness and a near 100% treatment completion record.
However, no funding is provided for food, travel to clinics or
basics such as bedding and cooking equipment. Currently, the
Homerton TB team provide a small sum on a weekly basis
through charitable donations and previously with the support
of TB Alert’s Patient Support Fund.
Another example of the need for housing has been high-
lighted in Ealing’s Joint Strategic Needs Assessment (JSNA)
2012–13 which stated:
TB is often associated with lower socio-economic status
and is quite prevalent in people who are homeless, have
been in prison, have mental health issues and have under-
lying chronic diseases such as diabetes and heart disease
that makes them more vulnerable for TB disease.
Therefore treatment can often be complex due to addition-
al complex medical conditions or it can be complex due to
difficult social conditions. Treatment should not be seen
solely as taking medication for six months or more, it
should be seen as providing holistic care taking into
account ability to take medication, ability to make the right
life choices and supporting vulnerable people in their cir-
cumstances in order that the health of the whole commu-
nity will improve as a result. This means that, in some
circumstances, a multi-stakeholder approach needs to
happen to ensure good adherence to treatment and an im-
provement of the quality of life.
In the list of commissioning priorities they suggested:
‘Consider commissioning emergency housing for homeless
patients for the duration of their TB treatment’.
In London, the Find & Treat specialist outreach team
works alongside over 200 NHS and third sector front-line ser-
vices to tackle TB among homeless people, drug or alcohol
users, vulnerable migrants and people who have been in
prison. The service screens almost 10 000 people a year using
mobile digital chest radiology; locates patients who have
stopped TB treatment before completing the full course; sets
up and supports directly observed treatment in the commu-
nity; and provides practical assistance and advice on accom-
modation, working in partnership with other services to
provide residential TB treatment and care for homeless and
destitute patients.
Conclusion
It is vital to address the treatment of TB in conjunction with
related health and social care issues. This requires a co-
ordinated approach to commissioning that includes not only
clinical services but also community support throughout the
duration of treatment, with a special focus on poor, margina-
lized and disadvantaged groups who bear the main burden of
the disease. There is clear evidence that following NICE and
RCN guidance results in cost-effective treatment outcomes
and is in the best interests of wider public health.
Recommendations
(i) Local TB commissioners should ensure integrated treat-
ment and care programmes are established through a
multi-agency approach, involving clinicians, relevant
local authority teams, public health professionals and
appropriate community organizations.
(ii) Local TB control strategies should address all aspects of
TB prevention, care and control including housing and
social support.
(iii) Joint strategic needs assessments in areas with high inci-
dence of TB should highlight local authorities’ dual roles:
their responsibility for public health, and the need to
provide housing and appropriate social care to TB patients.
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